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Abstract 
Background: Acute kidney injury (AKI) occurs frequently in hospitalized patients and has been associated with the 
administration of certain medications. Concerns have been raised in recent reports that the antibiotic combination of 
vancomycin and piperacillin/tazobactam (combV/P) may be more associated with AKI than monotherapy with either 
drug.
Methods: To compare the incidence of and risk factors for AKI in patients receiving combV/P versus monotherapy 
with either drug, a retrospective study was conducted in non-critically ill inpatients at a large urban teaching hospital. 
AKI was defined as either: (1) Increase in serum creatinine ≥0.5 mg/dl OR (2) ≥1.5-fold creatinine increase from admis-
sion baseline. In addition to standard multivariable regression adjustment, propensity score weighting was used as a 
robust approach to reduce the effects of covariate confounding when estimating the adjusted odds of AKI.
Results: A total of 228 patients were evaluated. The overall incidence of AKI was 11.8 % (27 of 228 patients). AKI 
occurred in 4 of 101 patients in the vanc group (4.0 %), 4 of 26 patients in the piptazo group (15.4 %), and 19 of 
101 patients in the combV/P group (18.8 %). The univariable odds of AKI was significantly lower in the vanc group 
compared to both the combV/P group (OR 0.178, 95 % CI 0.058–0.544, p = 0.003) and piptazo (OR 0.227, 95 % CI 
0.053–0.978, p = 0.047) group. A multivariable model accounting for baseline characteristics again showed that vanc 
monotherapy was associated with lower odds of AKI than combV/P (OR 0.14, 95 % CI 0.04–0.52, p = 0.004). Male sex 
was also associated with lower odds of AKI (OR 0.28, 95 % CI 0.10–0.79, p = 0.02) in the multivariable model. In the 
propensity score analysis using inverse probability of treatment weighting (IPTW), vanc monotherapy and male sex 
were again associated with lower odds of AKI (OR 0.17; 95 % CI 0.04–0.62, p = 0.008 and OR 0.28, 95 % CI 0.09–0.89, 
p = 0.03, respectively).
Conclusion: This study substantiates recent reports that combV/P may be more associated with AKI than vanc 
monotherapy in hospital inpatients. AKI also appears to be more likely in females during therapy with these antimicro-
bials. While severity of illness is difficult to account for, these findings are further justification for narrowing antibiotic 
coverage when possible after this combination has been initiated in hospitalized patients.
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Background
The administration of early broad spectrum antibiotic 
therapy is important in the management of common 
infectious syndromes such as sepsis and health-care asso-
ciated pneumonia [1]. As a result, point prevalence rates 
are high for antibiotic use in hospitalized patients [2]. 
However, antibiotics are sometimes used inappropriately 
and are associated with multiple adverse effects [3–5].
Acute kidney injury (AKI) during hospitalization 
occurs in approximately 5–20  % of inpatients and is an 
independent risk factor for mortality [6, 7]. AKI in this 
setting may occur in association with pharmaceutical 
agents such as intravenous contrast agents, non-steroidal 
anti-inflammatory drugs (NSAIDs), anticancer drugs, 
and antimicrobials [7].
Two antibiotics that are commonly used in hospital-
ized patients are vancomycin (vanc) for gram positive 
coverage and piperacillin/tazobactam (piptazo) for gram 
negative coverage. These two antimicrobials are often 
used in combination [8]. Given that nephrotoxicity has 
been associated with each of these antimicrobials [9, 10], 
we sought to determine if the risk of AKI is higher dur-
ing combination vanc + piptazo therapy (combV/P) than 
during monotherapy with either agent in non-critically ill 
hospitalized patients. While studies focusing on intensive 
care unit (ICU) patients suggest that AKI may be associ-
ated with comb V/P, ICU patients have many confound-
ers that increase their risk for AKI, including hypotension 
and shock [11]. Similar evidence from the non-critically 
ill hospitalized population has been heretofore lacking 
but is needed given that typically less than 10 % of hospi-
talized patients are admitted to intensive care units [12].
Methods
We performed a retrospective study using the electronic 
medical record. Adult patients who were initiated on 
vanc and/or piptazo from January 2011 to March 2013 at 
Grady Health System (GHS), an urban academic medical 
center in Atlanta, were screened. Patients were excluded 
for the following reasons: (1) admission/transfer to inten-
sive or intermediate care unit, (2) antibiotic use <48  h 
(subjects who experienced AKI prior to 48 h but antibi-
otics were continued beyond this timepoint were eligible 
for inclusion), (3) age <18 years, or (4) hemodialysis prior 
to therapy. AKI was defined by at least one of the two 
following: (1) ≥1.5-fold creatinine increase from admis-
sion baseline. (2) Increase in serum creatinine ≥0.5 mg/
dl from admission baseline. Criterion 1 represents the 
lowest level of kidney injury defined by the RIFLE (risk, 
injury, failure, loss, end-stage kidney disease) scoring sys-
tem, which has been used in multiple studies and shown 
to be associated with in-hospital mortality [13, 14]. Cri-
terion 2 has been proposed as a sensitive measure of 
kidney injury that also allows for detection in patients 
with higher baseline creatinine levels yet remains asso-
ciated with length of stay and mortality [6]. An explora-
tory analysis was also performed with the most inclusive 
measure of AKI we could find (serum creatinine increase 
≥0.3  mg/dl as defined by the Acute Kidney Injury Net-
work) [14, 15].
The primary outcome was the difference in AKI inci-
dence between patients receiving vanc, piptazo or 
combV/P. Secondary outcomes included examination of 
risk factors for AKI. Concomitant nephrotoxic agents 
(defined as use within 24 h of vanc or piptazo) were intra-
venous (IV) contrast, aminoglycosides, amphotericin, 
NSAIDs and tenofovir. The following comorbidities were 
included: diabetes mellitus, hypertension, human immu-
nodeficiency virus (HIV) infection, malignancy, and 
chronic kidney disease (CKD). CKD was defined as GFR 
<60 and was calculated automatically via the Modifica-
tion of Diet in Renal Disease (MDRD) equation. Vanc and 
piptazo were dosed according to a hospital nomogram 
(Fig. 1).The study was approved by the Emory University 
Institutional Review Board and Grady Memorial Hospital 
Research Oversight Committee. As this was a retrospec-
tive study, we obtained a formal waiver of subject consent 
from both oversight groups.
Statistical analysis
As per published literature, we estimated an inpatient 
AKI incidence of 10 % [6, 7]. With a rate of 10 %, a sam-
ple size of 100 non-critically ill hospitalized patients 
in each group produced a two-sided 95  % confidence 
interval with a width approximately 12  %. Additionally 
a sample size of 100 patients per antibiotic group (comb 
V/P versus monotherapy) provided 88 % power to detect 
a difference of 15  % in the proportion of patients with 
inpatient AKI (two-sided Fisher’s exact test; significance 
level = 0.05). This power calculation assumed that 20 % 
of patients receiving comb/V/P developed AKI and that 
there was a reduction to 5 % in the monotherapy groups. 
Data analysis was performed using SAS software. The 
potential associations with AKI were evaluated using 
the Chi square test or Fisher’s exact test. Baseline patient 
characteristics and risk factors significant to at least 
a P  ≤  0.10 were used in multiple logistic regression 
analysis.
Bootstrap bagging was used to identify stable and reli-
able predictors of AKI [16]. In brief, 1000 data sets were 
obtained by random sampling with replacement, auto-
mated forward stepwise regression was performed, and 
variables with p  <  0.05 were identified. After aggrega-
tion of all analyses, variables appearing in 50 % or more 
of them were selected as reliable associations. In the final 
model, the odds ratio and its 95  % confidence interval 
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were calculated for each factor in the presence of the 
others.
In addition, we performed a propensity score analy-
sis incorporating the two groups with significant num-
bers of patients (vanc and combV/P groups). This was 
undertaken in order to account for treatment selection 
bias (i.e., systematic differences in clinical characteristics 
between patients in the two treatment groups that may 
affect treatment selection). Propensity scores or balanc-
ing scores were estimated using binary logistic regression 
with Vanc (vs combV/P) as the dependent variable. The 
independent variables for the propensity score model 
included covariates associated with treatment, outcome, 
and treatment and outcome. Covariates were included 
when the presence of the variable was found to be differ-
ent in the univariate analysis between the two antibiotic 
groups with p value ≤0.1. Additionally, covariates were 
included that were found to have significant reliability 
>50 % in the first multivariable model with bootstrapping. 
The propensity or probability of receiving a particular 
Fig. 1 a GHS Vancomycin dosing guideline. b GHS Piperacillin–tazobactam dosing guideline
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treatment was calculated for each patient conditional on 
the covariates until an optimal balance on these covari-
ates was achieved. To adjust for treatment selection bias, 
each patient was assigned a “weight” or influence when 
estimating the effect of treatment on acute kidney injury. 
The weight for each patient was inversely proportional 
to the probability of receiving the treatment to which 
they were assigned in reality (IPTW, inverse probability 
of treatment weighting). The weights were used in a pro-
pensity score-weighted logistic regression to determine 
the effect of treatment on AKI. Standardized differences 
were used to assess the balance of confounders between 
the two treatment groups using methods described by 
Austin [17]. A standardized difference less than 0.1 sug-
gests negligible difference in the mean or prevalence of a 
covariate between treatment groups.
Results
A total of 1172 patients were reviewed. 944 patients 
met exclusion criteria (586 patients were excluded due 
to ICU or intermediate care unit transfer, 353 patients 
received antibiotics for less than 48 h, and 5 patients were 
excluded due to hemodialysis receipt).Therefore, a total of 
228 patients were identified after review of 26 months of 
inpatient admissions: 101 patients on vanc monotherapy, 
26 patients on piptazo monotherapy, and 101 patients on 
combV/P. Baseline patient characteristics including age, 
gender, race, renal function in creatinine clearance based 
on Cockcroft and Gault equation (CrCl), and body mass 
index (BMI) are listed in Table 1. The majority of patients 
were male (64.9 %) and African-American (79.8 %). Co-
morbidities were common (39.9  % had hypertension, 
21.9 % had HIV, and 21.5 % had diabetes). The most com-
mon indications for antibiotic usage were skin/soft tissue 
infection followed by pneumonia, bone or joint infec-
tion, and sepsis of unknown etiology. Piptazo doses were 
appropriate according to renal function in >90 % of cases 
and vancomycin doses were greater than 4  g daily in 
<5 % of cases. Median time of antibiotic exposure for the 
patients with AKI was 68, 61 and 46 h for vanc, piptazo 
and combV/P groups respectively (all p  >  0.05 between 
groups).
The overall incidence of AKI in the study was 11.8  % 
(27 of 228 patients). AKI occurred in 4 of 101 patients 
in the vanc group (4.0 %), 4 of 26 patients in the piptazo 
group (15.4  %), and 19 of 101 patients in the combV/P 
group (18.8  %). None of the patients required renal 
replacement therapy due to AKI. However, there were 
significant differences between the antibiotic treatment 
groups in demographic characteristics (Table 2). Patients 
receiving piptazo monotherapy were less likely to be 
African-American (61.5  %) than those on vanc mono-
therapy (83.2 %, p = 0.02) or combV/P (81.2 %, P = 0.03). 
Patients receiving piptazo monotherapy were more likely 
to be on concomitant NSAID therapy (34.6 %) than those 
on vanc monotherapy (13.0  %, p  =  0.01) or combV/P 
(8.9  %, P =  0.001). Other nephrotoxic agents that were 
examined (intravenous contrast, tenofovir, and amino-
glycosides) were not used at significantly different rates 
between antibiotic groups. None of the patients in the 
study received other agents known to be associated with 
nephrotoxicity including amphotericin and calcineurin 
inhibitors.
Overall, patients on vanc or piptazo monotherapy had 
fewer cumulative comorbidities than those on combV/P. 
Table 1 Baseline patient characteristics
SD standard deviation
a n = 228 unless otherwise stated
Characteristica N (%) [Mean, SD]
Years of age [48.7, 15.3]
Male sex 148 (64.9)
Race
 African American 182 (79.8)
 Caucasian 34 (14.9)
 Hispanic 6 (2.6)
 Native Hawaiian 1 (0.4)
 Asian 2 (0.9)
 Native American 2 (0.9)
 Other 1 (0.4)
CrCl (ml/min) (n = 187) [74.3, 32.8]
BMI (n = 187) [26.8, 9.2]
Nephrotoxic agents
 IV contrast 50 (21.9)
 Aminoglycoside 8 (3.5)
 NSAID 31 (13.7)
 Tenofovir 13 (5.7)
 2 or more agents 17 (7.5)
Comorbidities
 Diabetes 49 (21.5)
 Hypertension 91 (39.9)
 Malignancy 16 (7.0)
 CKD 12 (5.3)
 HIV 50 (21.9)
 2 or more of the above comorbidities 65 (28.5)
Indication for antibiotics
 Sepsis unknown etiology 26 (11.8)
 Pneumonia 44 (19.3)
 Bacteremia 7 (3.1)
 Skin/soft tissue infection 76 (33.3)
 Intra-abdominal 20 (8.8)
 Central nervous system 2 (0.9)
 Urinary tract 9 (4.0)
 Bone/joint 41 (18.0)
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Specifically, patients on vanc were less likely to have 
hypertension (p  =  0.01) and diabetes (p  =  0.02) com-
pared to patients on combV/P. Patients on piptazo were 
less likely to have HIV than patients on vanc (p = 0.03) 
or combV/P (p = 0.01). Not surprisingly, the indications 
for antibiotics were also significantly different between 
groups. Compared to patients on vanc and combV/P, 
patients on piptazo were significantly more likely to have 
urinary tract infection and intra-abdominal infection 
but significantly less likely to have bone/joint infection. 
Patients on combV/P were significantly more likely to 
have pneumonia than patients on vanc or piptazo mono-
therapy (all P < 0.05).
In the univariable analysis (Table  3), the odds of AKI 
were lower in the vanc group compared to both the comb 
V/P group (OR 0.178, p  =  0.003) and to the piptazo 
Table 2 Baseline characteristics by antibiotic










p value (vanc vs 
piptazo)





p value  
(overall)
Age: mean (sd) 47.00 (15.85) 47.58 (13.22) 50.71 (15.11) 0.21
Female sex (%) 39 (38.61 %) 9 (34.62 %) 32 (31.68 %) 0.59
African American (%) 84 (83.17 %) 16 (61.54 %) 82 (81.19 %) 0.02* 0.71 0.03* 0.04
CrCl in ml/min: 
mean (sd)




 0 agent 63 (63.00 %) 17 (65.38 %) 64 (63.37 %)
 1 agent 29 (29.00 %) 6 (23.08 %) 31 (30.69 %)
 2 agents 6 (6.00 %) 3 (11.54 %) 6 (5.94 %)
 3 agents 2 (2.00 %) 0 0
Number of comor-
bidities
0.26 0.0012* 0.0026* 0.0006
 0 46 (45.54 %) 16 (61.54 %) 26 (25.74 %)
 1 34 (33.66 %) 5 (19.23 %) 36 (35.64 %)
 2 17 (16.83 %) 4 (15.38 %) 34 (33.66 %)
 3 4 (3.96 %) 1 (3.85 %) 5 (4.95 %)
BMI: mean (sd) 26.75 (9.72) 30.27 (10.05) 26.07 (8.23) 0.20
IV contrast 23 (22.77 %) 3 (11.54 %) 24 (23.76 %) 0.39
Aminoglycoside 5 (4.95 %) 0 3 (2.97 %) 0.44
NSAID 13 (13.00 %) 9 (34.62 %) 9 (8.91 %) 0.0097* 0.35 0.0008* 0.003
Tenofovir 6 (5.94 %) 0 7 (6.93 %) 0.39
Diabetes 16 (15.84 %) 3 (11.54 %) 30 (29.70 %) 0.58 0.02* 0.06 0.02
Hypertension 32 (31.68 %) 10 (38.46 %) 49 (48.51 %) 0.51 0.01* 0.36 0.05
Malignancy 5 (4.95 %) 2 (7.69 %) 9 (8.91 %) 0.54
CKD 5 (4.95 %) 0 7 (6.93 %) 0.36
HIV 22 (21.78 %) 1 (3.85 %) 27 (26.73 %) 0.03* 0.41 0.01* 0.04
Indication for anti-
biotics
Pneumonia 15 (14.85 %) 1 (3.85 %) 28 (27.72 %) 0.1899 0.03* 0.0097* 0.0072
bacteremia 5 (4.95 %) 0 2 (1.98 %) 0.46
SSTI 40 (39.60 %) 4 (15.38 %) 32 (31.68 %) 0.06
Abdominal 1 (0.99 %) 15 (57.69 %) 4 (3.96 %) <0.0001* 0.37 <0.0001* <0.0001
CNS 2 (1.98 %) 0 0 0.61
UTI 3 (2.97 %) 5 (19.23 %) 1 (0.99 %) 0.0091* 0.62 0.0013* 0.0003
Bone or joint infec-
tion
25 (24.75 %) 0 16 (15.84 %) 0.0046* 0.11 0.04* 0.01
Sepsis of unknown 
etiology
10 (10.20 %) 1 (4.55 %) 15 (15.00 %) 0.31
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Table 3 Univariable analysis for AKI [27 of 228 (11.8 %) patients with AKI]
P values <0.05 denoted by italics face plus asterisk
Risk factor Incidence AKI % with AKI Odds ratio 95 % CI P value
Treatment
 Vancomycin 4/101 4.0 0.178 (0.058, 0.544) 0.003*
 Piperacillin/tazobactam 4/26 15.4 0.785 (0.242, 2.545) 0.69
 Combination vanc + piptazo 19/101 18.8 1.0
 Vanc 0.227 (0.053, 0.978) 0.047*
 Piptazo 1.0
Age
 Per 1 year increase 0.994 (0.968, 1.021) 0.69
Sex
 Male 11/148 7.4 0.321 (0.141, 0.731) 0.007*
 Female 16/80 20.0
Race
 Caucasian 1/34 2.2 1.0
 African-American 26/182 14.3 5.5 (0.721–41.968) 0.10
BMI
 ≥30 kg/m2 9/43 20.9 2.667 (1.053, 6.760) 0.04*
 <30 kg/m2 13/144 9.0 1.0
Creatinine clearance
 <Median of 71.94 ml/min 11/95 11.6 0.964 (0.396, 2.347) 0.94
 ≥Median of 71.94 ml/min 11/92 12.0 1.0
 Per 10 ml/min decrease 1.048 (0.922, 1.192) 0.47
Nephrotoxic agents
 IV contrast, yes 8/50 16.0 1.594 (0.652, 3.894) 0.31
 IV contrast, no 19/178 10.7 1.0
 Aminoglycoside, yes 1/8 12.5 1.066 (0.126, 9.014) 0.95
 Aminoglycoside, no 26/220 11.8 1.0
 NSAIDs, yes 5/31 16.1 1.521 (0.530, 4.368) 0.44
 NSAIDs, no 22/196 11.2 1.0
 Tenofovir, yes 2/13 15.4 1.382 (0.290, 6.599) 0.68
 Tenofovir, no 25/215 11.6 1.0
 ≥2 agents 1/17 5.9 0.445 (0.057, 3.495) 0.44
 <2 agents 26/211 12.3 1.0
Diabetes
 Yes 7/49 14.3 1.325 (0.525, 3.343) 0.55
 No 20/179 11.2 1.0
Hypertension
 Yes 14/91 15.4 1.734 (0.774, 3.886) 0.18
 No 13/137 9.5 1.0
Malignancy
 Yes 3/16 18.8 1.808 (0.480, 6.803) 0.38
 No 24/212 11.3 1.0
CKD
 Yes 2/12 16.7 1.528 (0.317, 7.377) 0.60
 No 25/216 11.6 1.0
HIV
 Yes 6/50 12.0 1.020 (0.388, 2.681) 0.97
 No 21/178 11.8 1.0
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monotherapy group (OR 0.227, p  =  0.047). There was 
no significant difference in AKI between the piptazo and 
combV/P groups. For the exploratory analysis using the 
most conservative measure of AKI (creatinine increase 
of at least 0.3 mg/dl), the frequency was again higher in 
the combV/P group (26 of 101 or 25.7 %) compared to the 
vanc monotherapy group (11 or 101 or 10.9 %, p = 0.006). 
Also in this exploratory analysis, AKI occurred in 6 of 26 
patients (23.1 %) of the piptazo group, which was not sta-
tistically different compared to the vanc group (p = 0.10) 
or compared to the combV/P group (p = 0.78).
Table  3 shows demographic variables that by uni-
variable analysis (p ≤ 0.10 for inclusion in multivariable 
model) were associated with increased or decreased odds 
of AKI: male gender, OR 0.321 (95  % CI 0.141–0.731, 
p = 0.007), BMI ≥30 kg/m2, OR = 2.667 (95 % CI 1.053–
6.760, p = 0.04), and African-American race compared to 
caucasian OR 5.5 (95 % CI 0.721–41.968 p = 0.10). Of the 
indications for antibiotics (not listed in Table  3), pneu-
monia (OR 3.50, 95  % CI 1.491–8.219, p  =  0.004) was 
associated with higher odds of AKI while skin/soft tissue 
infection (OR 0.137, 95 % CI 0.032–0.596, p = 0.008) was 
associated with a lower odds for AKI. Intra-abdominal 
infection (OR 2.819, 95 % CI 0.934–8.504) tended to have 
higher odds of AKI (p = 0.07).
For the traditional multivariable analysis with logis-
tic regression, there were 179 patients, 22 with AKI (see 
Table  4). By bootstrap bagging, the following factors 
occurred in over 50 % of models and were thus kept in the 
model: antibiotic group (84.1  %), sex (67.4  %), baseline 
creatinine clearance (per 10  ml/min increase) (65.4  %), 
African-American versus caucasian race (57.3  %), and 
skin/soft tissue infection (52.1  %). The other factors 
from Tables 2 and 3 with p ≤ 0.10 occurred in <50 % of 
models and thus were not kept in the model. In the final 
model, vanc monotherapy (OR 0.14, 95 % CI 0.04–0.52, 
p = 0.004) as well as piptazo monotherapy (OR 0.15, 95 % 
CI 0.03–0.83, p = 0.03) were associated with lower odds 
of AKI compared to comb V/P. Male sex was also associ-
ated with lower odds of AKI (OR 0.28, 95 % CI 0.10–0.79, 
p =  0.02). There was also a trend for increasing creati-
nine clearance to be associated with higher odds of AKI 
(p = 0.05) and for skin/soft tissue infection to be associ-
ated with lower odds of AKI (p = 0.06).
Given the very small number of patients in the piptazo 
group, we henceforth focused the propensity score logistic 
regression analysis on only the vanc and combV/P groups. 
The significant covariates from Tables  2 and 4 included 
race, baseline creatinine clearance, pneumonia, diabetes, 
hypertension and skin/soft tissue infection. We did not 
include subjects who lacked creatinine clearance data in the 
propensity score analysis, leaving 161 subjects to be ana-
lyzed by IPTW (see Table 5). Vanc monotherapy again was 
associated with a decreased odds ratio for AKI compared to 
combV/P (adjusted OR 0.17; 95 % CI 0.04–0.62, p = 0.008). 
Male sex was also again associated with decreased odds 
ratio for AKI (adjusted OR 0.28, 95  % CI 0.09–0.89, 
p = 0.03). There were no other statistically significant asso-
ciations with AKI in the propensity score analysis.
Discussion
Given the high frequency of infections in hospitalized 
patients caused by drug resistant pathogens, empiric 
broad spectrum antibiotic use will be common for the 
foreseeable future. In this retrospective study of non-
critically ill inpatients, we found that compared to vanc 
monotherapy, the odds of AKI were over five times 
higher during combV/P therapy. We also found that odds 
of AKI were significantly lower for males during therapy 
with these antibiotics. These associations remained sta-
tistically significant in the multivariable analyses that 
included propensity scoring.
Table 4 Multivariable logistic regression analysis for factors associated with AKI (179 patients and 22 with AKI)
Risk factors with reliability less than 50 % included pneumonia (48 %), hypertension (33 %), BMI (28 %), NSAIDS (25 %), bone or joint infection (19 %), diabetes (13 %), 
HIV (11 %), and total number of comorbidities (10 %)
a Percentage of times each risk factor appeared in 1000 bootstrap multivariable analyses. Risk factors with reliability <50 % were not included in the multivariable 
model
Risk factor Odds ratio (95 % CI) P Reliabilitya (%)
Antibiotic group 0.01 84.6
 Vanc versus combV/P 0.14 (0.04, 0.52) 0.004
 Piptazo versus combV/P 0.91 (0.22, 3.82) 0.89
 Vanc versus piptazo 0.15 (0.03, 0.83) 0.03
Sex (male/female) 0.28 (0.10, 0.79) 0.02 67.4
Baseline creatinine clearance (per 10 ml/min increase) 1.15 (1.00, 1.33) 0.05 65.4
Race (African-American/Caucasian) 5.34 (0.62, 46.4) 0.13 57.3
Skin/soft tissue infection (yes/no) 0.22 (0.05, 1.05) 0.06 52.1
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At the time of this study, there was a paucity of pub-
lished data examining the incidence of AKI with combV/P 
therapy versus monotherapy with either agent, particu-
larly in hospitalized patients who are not critically ill [18, 
19]. Since we completed our analysis, however, two stud-
ies were published in 2014 that focused on this question in 
non-critically ill hospitalized patients [20, 21]. Each study 
incorporated definitions of AKI similar to ours and both 
also showed that combV/P was independently associated 
with AKI compared with vanc monotherapy. In the study 
by Burgess et al., 191 patients who had received treatment 
with vancomycin were analyzed. In a multivariable analy-
sis, comb V/P was associated with an AKI odds ratio of 
2.48 (p =  0.032) compared to vanc monotherapy. In the 
study by Meaney et al., 125 patients treated with vancomy-
cin were analyzed. Again, comb V/P was associated with 
an AKI odds ratio of 5.36 (95 % CI 1.41–20.5) compared 
to vanc monotherapy in multivariate analyses. Our study 
provides further proof of this association and extends the 
finding to a setting in which patients are predominantly 
African-american. Our study provides additional evidence 
through a propensity score analysis that shows the same 
statistically significant AKI odds ratio associated with 
combV/P. While a randomized controlled trial would be 
ideal to evaluate such risks, propensity score analysis can 
provide an estimate of the likelihood of exposure based on 
demographics and other co-morbidities.
The mechanisms that could underpin AKI during 
combV/P are not clear at this time. Beta lactam agents, 
in particular penicillin derivatives, are purported to cause 
AKI through interstitial nephritis [22]. Interestingly, the 
study by Meaney et  al. found that almost one-third of 
patients with AKI also had either eosinophilia or eosin-
ophiluria. This may be additional evidence that AKI on 
combV/P may be in part immune mediated. It should 
be noted that there are conflicting reports on whether 
combV/P is more associated with AKI than the combina-
tion of vancomycin and cefepime and other cephalospor-
ins [23, 24]. Therefore, AKI during combination therapy 
with vancomycin and beta-lactams may or may not be 
a class effect. Larger prospective studies are needed to 
more definitively address this question.
Our multivariable analysis showed that female patients 
were more likely to develop AKI during treatment with 
at least one of the two antimicrobials in the study. To our 
knowledge this finding has not been previously reported, 
but female gender has been identified as a risk fac-
tor for AKI in the most recent Kidney Disease Improv-
ing Global Outcomes (KDIGO) statement [25]. The 
mechanism for this is unclear, but based on our study 
clinicians should be aware that female inpatients may 
be at higher risk for AKI during treatment with vanc or 
piptazo. Unexpectedly, we found a trend for increased 
AKI odds with increasing creatinine clearance (by 10 ml/
min increase). This association is counterintuitive but has 
also been found in at least two other studies of vancomy-
cin nephrotoxicity which also used the Cockroft-Gault 
(CG) equation for estimate of renal function [21, 26]. 
Both antibiotics are dosed renally meaning that patients 
with higher CrCl are often given a higher dose of drug. 
This may have played a role in this finding. However, 
this association became statistically non-significant in 
the propensity score analysis. We also acknowledge that 
the CG equation is not considered the gold standard for 
measurement of renal function and has variability based 
on body surface area [27]. It would be ideal to measure 
glomerular filtration rate directly in order to gauge renal 
function, but the feasibility of accomplishing this in a 
large study is significantly lower.
We acknowledge the other limitations of our study. 
Propensity scoring is one way to compare the risks of 
exposure to drug (and thus can in some ways account for 
demographic and disease differences), but is not a per-
fect substitute for a randomized trial. For example, the 
lower odds of AKI associated with skin/soft tissue infec-
tion could be a reflection of less severe illness and may 
have influenced the finding of lower AKI odds in the vanc 
monotherapy group. While we attempted to account 
for illness severity in the multivariable analysis and pro-
pensity score analysis by including comorbidities and 
indication for antibiotics, we were not able to perform 
analyses of illness severity as measured by scores such as 
APACHE (Acute Physiologic Assessment and Chronic 
Health Evaluation) and other equations [28]. Ideally, pro-
spective studies are necessary to address causality and 
a randomized clinical trial would be the most rigorous 
means to determine a causal treatment effect.
We also acknowledge the lack of collection of some 
data points, including duration of hospitalization. We 
Table 5 Logistic regression with  inverse probability 
of  treatment weighting to  address treatment selection 
bias (n = 161)
Risk factor Odds ratio (95 % CI) P
Antibiotic group
 Vanc versus combV/P 0.17 (0.04, 0.62) 0.008
Sex (male/female) 0.28 (0.09, 0.89) 0.03
Baseline creatinine clearance (per 10 ml/
min increase)
1.14 (0.97, 1.34) 0.11
Race (African-American/Caucasian) 5.67 (0.47, 68.40) 0.17
Skin/soft tissue infection (yes/no) 0.49 (0.11, 2.25) 0.36
Pneumonia (yes/no) 2.25 (0.63, 8.07) 0.21
Diabetes (yes/no) 0.77 (0.19, 3.17) 0.71
Hypertension (yes/no) 1.78 (0.55, 5.78) 0.34
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also were not able to evaluate the potential role of van-
comycin concentrations in this study of AKI. While very 
few patients in the group as a whole were given vanco-
mycin dosing greater than the 4  g daily threshold that 
has been shown to be associated with AKI, we were not 
able to specifically analyze whether this was a risk factor 
for AKI at an individual level. We also did not analyze 
the data with respect to the companies that provided the 
drugs over the course of the study.
We did not assess the reversibility of AKI over time, but 
did find that there were no patients who required renal 
replacement therapy during the hospitalization. As with 
other recently published studies, we excluded patients 
who received antibiotics for less than 48 h [20, 21]. How-
ever, other study designs may have been appropriate, such 
as including all patients who had at least one dose of anti-
biotic. For the definition of AKI in our study, we chose to 
include the lowest level of injury defined by the RIFLE cri-
teria as well as an additional criterion that has been advo-
cated by some experts to define AKI. It is possible that the 
use of these two criteria was overly inclusive and that the 
results may have been different if a more stringent defini-
tion of AKI had been used. However, we believe that an 
inclusive definition was appropriate for this study given 
that even low levels of renal injury have been associated 
with poor clinical outcomes in hospitalized patients [14]. It 
is also possible that our definition of AKI was not inclusive 
enough. However, an exploratory analysis using a particu-
larly inclusive measure of AKI also showed increased AKI 
in those on combV/P compared to vanc monotherapy.
Conclusions
In summary, in a sample of non-critically ill inpatients, we 
found increased odds for acute kidney injury associated 
with combination vancomycin + piperacillin/tazobactam 
compared to vancomycin monotherapy. Additionally, we 
found female sex to be independently associated with AKI 
during therapy with these antimicrobials. The associations 
remained significant in robust multivariable analyses and 
propensity score analyses. These findings provide further 
justification for narrowing antibiotic coverage when pos-
sible after this combination has been initiated in hospital-
ized patients. Larger multicenter prospective studies are 
needed to confirm these findings.
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